Introduction {#section1-0269881116654697}
============

Antipsychotic drugs are the primary medications for the treatment of schizophrenia and other neuropsychiatric disorders with a psychosis component (e.g. amphetamine psychosis, psychosis in Alzheimer's disease, psychosis in Parkinson's disease, etc.). Since the introduction of chlorpromazine in psychiatry in 1952, about 50 additional antipsychotic drugs have been developed for the treatment of schizophrenia. They are all significantly more effective than placebo and are often classified into two groups, typical (or first generation) and atypical (or second generation), with atypical drugs offering a reduced risk of extrapyramidal motor syndromes (EPS) ([@bibr59-0269881116654697]), although recent studies have questioned the validity of such a classification system ([@bibr73-0269881116654697]). The differences in efficacy among various commonly prescribed antipsychotic drugs are small yet robust, with clozapine being more efficacious than all the other drugs (e.g. amisulpride, olanzapine, risperidone, paliperidone, zotepine, haloperidol, quetiapine, aripiprazole, etc.).

Much research on antipsychotic drugs has four interconnected goals in mind. The first one is to understand the mechanisms of action of antipsychotic drugs at various levels (e.g. molecular, cellular, neural network, and behavioral) in an attempt to answer the basic question of how antipsychotic drugs work to achieve their therapeutic effects ([@bibr57-0269881116654697], [@bibr61-0269881116654697]). There have been attempts to link actions of antipsychotic drugs at various receptor sites, notably dopamine D~2~, serotonin (5-HT)~2A~, and 5-HT~1A~ receptors ([@bibr58-0269881116654697]; [@bibr90-0269881116654697]; [@bibr118-0269881116654697]; [@bibr133-0269881116654697]) to their behavioral mechanisms of actions ([@bibr74-0269881116654697]). The second goal is to enhance our understanding of etiology and psychopathological mechanisms relevant for psychosis. The rationale is that dysfunction of the molecular targets of antipsychotic drugs such as D~2~ and 5-HT~2A~ can be a possible cause of psychotic symptoms ([@bibr135-0269881116654697]). The third one is to provide better assays for new drug discovery. With the increase of our understanding of etiology of psychosis, molecular and behavioral mechanisms of antipsychotic action, behavioral and molecular assays with better predictive validity could be developed to identify new compounds useful for psychosis ([@bibr5-0269881116654697]). The final one, which falls in the domain of behavioral neuroscience, is to use antipsychotic drugs as pharmacological tools to probe the neurochemical basis of behavior, as typical antipsychotic drugs such as haloperidol are potent D~2~ receptor antagonists and atypical drugs possess dual actions against serotonin 5-HT~2A~ and dopamine D~2~ receptors. Research discussed in this review has been largely aimed at the first goal.

One important feature associated with repeated or chronic antipsychotic treatment is the alterations of drug sensitivity, a phenomenon largely ignored in the field of behavioral pharmacology in recent decades. In comparison to extensive research on changes of drug sensitivity induced by psychotomimetic drugs (e.g. amphetamine, cocaine and PCP etc.) ([@bibr101-0269881116654697]; [@bibr121-0269881116654697]), antipsychotic-induced alterations are not as well understood. This situation is peculiar given the fact that antipsychotics, like drugs of abuse, are often taken repeatedly by people for a prolonged period of time, and increase in antipsychotic response is thought to be an important mechanism supporting the maintenance of antipsychotic effect ([@bibr60-0269881116654697]). One of the major issues which may have contributed to this lack of attention is the difficulty in demonstrating its existence consistently. For example, in animal studies using the prepulse inhibition paradigm, alterations in antipsychotic drug sensitivity have never been consistently established among different antipsychotics ([@bibr42-0269881116654697]; [@bibr78-0269881116654697]). On the other hand, clinical studies often focus on the efficacy, tolerability, and side effect profiles of individual drugs, overlooking the temporal course of changes in drug sensitivity. Also, changes in antipsychotic efficacy in human studies typically do not become apparent within a limited trial period. It often requires years of medication in order to induce such a change (e.g. supersensitivity psychosis, tardive dyskinesia (TD)).

Several years ago, when we started looking into this issue, there were limited and scattered reports. There was also a lack of terminology used to describe drug-induced long-term changes in drug sensitivity and no standardized approach to study these changes. Current psychiatrists and psychopharmacologists do not talk about long-term antipsychotic effects in these terms, let alone discuss their clinical implications. We thus borrowed two terms from the literature of drugs of abuse and defined "antipsychotic sensitization" and "antipsychotic tolerance" as reflecting the increased and decreased drug effects due to past drug use, respectively. Antipsychotic sensitization and tolerance reflect the long-term consequences of chronic antipsychotic drug treatment on the brain and behavioral functions and are thought to be mediated by drug-induced changes in neuroplasticity and basic psychological processes. Therefore, understanding the behavioral characteristics and neurobiological underpinnings of antipsychotic sensitization and tolerance should greatly enhance our understanding of mechanisms of antipsychotic action, and may help future drug discovery and improve clinical treatment of schizophrenia. This understanding may also provide a different perspective of looking at some clinical effects. For example, antipsychotic sensitization and tolerance may explain why some recent clinical trials of promising novel therapeutics fail to demonstrate efficacy ([@bibr43-0269881116654697]). The testing of novel compounds is often done in patients exposed to antipsychotic drugs (comparators) for years and briefly withdrawn. Due to the (cross)-tolerance effect, it is possible that prior antipsychotic exposure history and subsequent withdrawal affects the response of the brain to novel drugs to the extent that it effectively masks the true efficacy of novel compounds. On the other hand, as clinical responses of patients on novel compounds are often compared to those on treatment-as-usual (TAU) after a brief washout period. Re-exposure to the same drug may potentiate the TAU group's clinical responses to the comparator drug, masking the true efficacy of novel compounds from another perspective. In addition to these implications for antipsychotic drug research, because antipsychotic sensitization and tolerance share many similarities with behavioral sensitization and tolerance induced by other psychoactive drugs such as psychostimulants (e.g. amphetamine, methamphetamine, nicotine, etc.), opioids, and dissociative anesthetics (e.g. phencyclidine, ketamine, MK-801) ([@bibr108-0269881116654697]; [@bibr121-0269881116654697]), studies of antipsychotic sensitization and tolerance could expand our understanding of sensitization and tolerance phenomena in general, and introduce new research ideas, tools, approaches, and knowledge.

This review will provide an overview of recent research in this area. We will focus on animal work that examines the behavioral characteristics of antipsychotic sensitization and tolerance, the possible underlying neurobiological mechanisms, their developmental impacts and clinical implications. To show the clinical relevance of these phenomena, human studies on antipsychotic sensitization and tolerance will be briefly reviewed at the beginning. It should be noted that sensitization and tolerance can develop in various domains involving different organ systems (e.g. cardiovascular, liver, blood, endocrine, brain, etc.) ([@bibr29-0269881116654697]; [@bibr132-0269881116654697]). Because the behavior and associated brain functions are the focal targets of antipsychotics, we will restrict our use of antipsychotic sensitization and tolerance in the behavioral domain. Thus, we define *antipsychotic sensitization* as the consequence of repeated drug treatment that leads to *increased behavioral effects* of a drug, while *antipsychotic tolerance* as the *decreased behavioral effects*.

General issues {#section2-0269881116654697}
==============

It is worth mentioning three general principles at the outset. Readers who are familiar with behavioral sensitization and tolerance associated with drugs of abuse can easily recognize them. First, sensitization and tolerance develop to the specific effects of a drug, not to a drug itself. Like many psychoactive drugs, antipsychotic drugs typically have multiple behavioral and physiological effects due to their complex pharmacodynamic receptor actions ([@bibr93-0269881116654697]). It is thus possible that antipsychotic sensitization and tolerance may develop to one effect of a drug, but not to another ([@bibr153-0269881116654697]). It is also possible that sensitization is seen in one effect while at the same time tolerance is seen in others. Furthermore, the same drug may induce sensitization to a drug effect under some circumstances (e.g. dosage level, dosing regimen, and duration) but may induce tolerance to the same effect under other conditions ([@bibr148-0269881116654697]). The second point is that multiple processes and mechanisms are involved in the development of antipsychotic sensitization and tolerance. At the behavioral level, antipsychotic sensitization and tolerance reflect a general nonassociative learning and memory process in which an organism modifies its responses to an exogenous stimulus (e.g. a drug) based on its past experience with this stimulus. The learning and memory processes involved in antipsychotic sensitization and tolerance are not dissimilar to those involved in the basic forms of habituation and sensitization. Because the induction and expression of both effects depend on the context in which drug treatment occurs and on the specific motoric response that the drug targets ([@bibr34-0269881116654697]; [@bibr107-0269881116654697]; [@bibr154-0269881116654697]; [@bibr180-0269881116654697]), other associative processes (e.g. conditioning, drug-setting, behavioral response) may also play a role in the development of antipsychotic sensitization and tolerance. At the brain level, drug-induced plastic changes on receptor density, intracellular signaling, electrophysiological property of neurons, and neuroanatomic volume are examples of many processesthat antipsychotic sensitization and tolerance exert on. [@bibr45-0269881116654697]: 313) suggested that all these different processes and mechanisms associated with behavioral sensitization and tolerance can be classified into two general categories: "higher level mechanisms involving instrumental and classical conditioning processes, and more molecular mechanisms involving functional and dispositional adaptations." He also pointed out that it would be easier to "derive general "laws" of sensitization and tolerance at the level of the first class rather than the second." The third point is that many experimental and pharmacological factors influence the development of antipsychotic sensitization and tolerance. Notable factors include treatment schedule, drug dose, and behavioral testing conditions ([@bibr14-0269881116654697]; [@bibr115-0269881116654697]). Under some conditions, these factors could even determine whether a sensitization or tolerance will be developed ([@bibr68-0269881116654697]; [@bibr108-0269881116654697]). With these points in mind, we will first review some human studies that examined antipsychotic sensitization and tolerance and their roles in explaining therapeutic and side effects of antipsychotic treatment.

Clinical phenomena associated with antipsychotic sensitization and tolerance {#section3-0269881116654697}
============================================================================

Like other psychoactive drugs, antipsychotic drugs are known to induce various clinically relevant sensitization and tolerance effects in many behavioral domains, including both therapeutic and side effects ([@bibr30-0269881116654697]), resulting from the brain's adaptive responses to the bombardment of long-term antipsychotic drug treatment ([@bibr69-0269881116654697]; [@bibr131-0269881116654697]). The observations that psychotic symptoms improve over time and extrapyramidal side effects get worst after years of medication could be considered examples of antipsychotic sensitization. On the other hand, chronic antipsychotic treatment can also induce tolerance in certain behavioral domains, as evidenced by the findings that in comparison to patients with chronic antipsychotic treatment, first-episode schizophrenia patients respond to lower doses of antipsychotics; are more sensitive to side effects; and have comparatively higher response rates than chronic schizophrenia patients ([@bibr83-0269881116654697]; [@bibr64-0269881116654697]). These differences between drug naïve (first-episode) and drug experienced patients could be interpreted as a result of tolerance developed in the drug experienced group. The same drug treatment may induce sensitization in some patients, but tolerance in others ([@bibr145-0269881116654697]). Admittedly, the terms "antipsychotic sensitization" and "antipsychotic tolerance" have not been frequently used in describing many clinical phenomena. The above mentioned clinical phenomena could also be subject to other interpretations. However, as will become apparent, classifying antipsychotic phenomena in the framework of sensitization and tolerance would provide a unified theory (the brain's adaptation responses to the bombardment of long-term antipsychotic drug treatment) to better understand their underlying mechanisms. In this section, the four best known phenomena consistent with the conceptualization of antipsychotic sensitization and tolerance will be selectively reviewed, including: exponential time course of symptom improvement, time-dependent sensitization (TDS), supersensitivity psychosis, and TD ([@bibr1-0269881116654697]; [@bibr32-0269881116654697]; [@bibr60-0269881116654697]).

Exponential time course of symptom improvement {#section4-0269881116654697}
----------------------------------------------

When acute psychotic patients are treated with antipsychotic drugs, their symptoms improve gradually over time if they respond well to the chosen antipsychotic drugs. After 2--3 weeks of continuous treatment, a clear improvement can be noticed and patients report that they are less bothered by psychotic thoughts and bizarre perceptions ([@bibr60-0269881116654697]). Dopamine D~2~ receptor blockade is achieved within hours after drug administration ([@bibr98-0269881116654697]; [@bibr161-0269881116654697]), however, it is not well understood and heatedly debated as to why it still takes 2--3 weeks in order to see clear therapeutic benefits. Traditionally, it is thought that the *onset* of antipsychotic response is delayed for 2--3 weeks, even though the receptor actions of antipsychotic drugs are well established within minutes ([@bibr41-0269881116654697]). However, recent re-examinations of the time course of antipsychotic effect cast doubt on this long-held idea of delayed onset ([@bibr1-0269881116654697]; [@bibr61-0269881116654697]; [@bibr72-0269881116654697]). [@bibr1-0269881116654697] examined 42 double-blind, comparator-controlled studies (\>7000 patients) using a meta-analysis technique, and found that psychotic symptoms improved within the first week of treatment and showed a progressive improvement over subsequent weeks, with the overall pattern of improvement approximating an exponential curve. In addition, [@bibr62-0269881116654697] tested the hypothesis that psychosis improves within the first 24 h of antipsychotic treatment. They found that patients with schizophrenia receiving olanzapine (10 mg i.m.) or haloperidol (7.5 mg i.m.) treatment showed greater resolution of overall symptoms than those receiving placebo. An independent change in the psychotic symptoms, which included conceptual disorganization, hallucinatory behavior, or unusual thought content, was evident for both medications within the first 24 h of treatment. [@bibr72-0269881116654697] analyzed a large homogeneous database of original patient data from seven randomized, double-blind studies of the efficacy of amisulpride in patients with schizophrenia spectrum disorders and found the same results. Therefore, the time course of the antipsychotic action reveals a progressively enhanced response to antipsychotic drugs, a sensitization-like pattern. It can be conceptualized that the reason that psychotic symptoms improve over time and follow an exponential curve is because antipsychotic effect intensifies with repeated drug administration.

TDS {#section5-0269881116654697}
---

TDS is a controversial concept that is not well understood. It refers to the observation that a brief exposure to a psychotherapeutic drug such as antipsychotic or antidepressant drugs induces a clinical effect that grows with the passage of time ([@bibr10-0269881116654697]), an effect indicative of antipsychotic sensitization. [@bibr10-0269881116654697] have argued that TDS is a useful principle for the explanation of clinical improvement which grows with the passage of time, and a certain percentage of symptom improvement observed in patients is likely due to TDS. One direct implication is that "instead of managing disorders such as depression by multiple daily drug treatments, it may be possible to accomplish the same ends by treating once every few weeks." (p. 354). As discussed above, psychotic symptoms do improve exponentially with the passage of time and with the increase of treatment duration ([@bibr2-0269881116654697]; [@bibr60-0269881116654697]), but the relative contributions from each factor (i.e. time vs treatment duration) on symptom improvement has not been investigated. Currently, the most common practice in the clinic is to treat schizophrenic patients with antipsychotic drugs daily to achieve approximately 60%--80% of dopamine D~2~ receptor occupancy ([@bibr56-0269881116654697]). If we do not need to maintain a daily treatment schedule, it would avoid many side effects, including EPS and excess weight gain. Recent studies showing that dosing every 2--3 days is sufficient to maintain antipsychotic efficacy in schizophrenic patients is in support of this practice and the TDS principle ([@bibr117-0269881116654697], [@bibr116-0269881116654697]). This finding suggests that upon initial exposure, physiological events initiated by a drug enhance the antipsychotic's effects beyond its presence at the receptor, thereby inducing efficacy without requiring constant receptor binding. This idea is also supported by our recent preclinical findings that risperidone and asenapine sensitization persist and even increase to some degree with the passage of time ([@bibr38-0269881116654697]). More clinical and preclinical work is needed to determine how pharmacological factors and characteristics of patients influence TDS and identify relevant neurobiological mechanisms.

Supersensitivity psychosis {#section6-0269881116654697}
--------------------------

Supersensitivity psychosis refers to a drug-induced psychotic relapse following chronic neuroleptic treatment ([@bibr28-0269881116654697]; [@bibr67-0269881116654697]). It has been reported that in some patients with schizophrenia, their psychotic symptoms return following withdrawal or decrease of doses of antipsychotic drugs. Some patients also report experiencing negative effects in the process of drug withdrawal, including difficulty falling or staying asleep, mood changes, increases in anxiety/agitation, difficulty concentrating/completing tasks, headaches, memory loss, nightmares, nausea, and vomiting etc. ([@bibr125-0269881116654697]). The underlying mechanism is suggested to be the drug-induced increase in the mesolimbic dopamine postsynaptic D~2~ receptors. It is well known, especially in preclinical studies, that chronic use of antipsychotic drugs often elicits dopamine supersensitivity (up-regulation of D~2~^High^ receptors) ([@bibr136-0269881116654697]). The idea is that the cessation of chronic antipsychotic treatment induces a compensatory increase in the mesolimbic dopamine function, leading to psychotic relapse. Because supersensitivity psychosis is behaviorally (e.g. delusions, hallucinations, suspiciousness) and neurobiologically (e.g. increase in the mesolimbic dopamine function) similar to endogenous psychosis, reinstatement of antipsychotic treatment is efficacious to reduce this syndrome. In those patients, it is often observed that a gradual increase in the dosage is necessary to maintain a therapeutic effect, possibly due to the fact that antipsychotic treatment is needed to control both the endogenous psychosis and supersensitivity psychosis. This drug-induced increase in dosage increase indicates the development of tolerance to antipsychotic effect. In other words, the appearance of supersensitivity psychosis reflects the fact that chronic use of antipsychotic drugs causes a tolerance effect.

TD {#section7-0269881116654697}
--

TD is a human choreic movement disorder associated with chronic exposure to antipsychotic drugs, especially to those with strong dopamine receptor blocking capacity (e.g. haloperidol, chlorpromazine). Clinically, TD includes a broad spectrum of symptoms that develop after chronic use of antipsychotic drugs, including involuntary movements of the tongue, jaw, trunk, or extremities. Abnormal movements could appear during treatment or withdrawal from the treatment, and typically persist for at least one month. The incidence of TD has not dramatically reduced with the widespread use of atypical antipsychotic drugs, suggesting that the common D~2~ blocking action of all antipsychotics is likely the main cause ([@bibr11-0269881116654697]).

TD is thought to reflect an antipsychotic sensitization effect in the side effect domain, as the syndromes emerge and deteriorate over time (however, see ([@bibr108-0269881116654697])). The traditional view of the neurobiological mechanism of TD emphasizes the role of drug-induced upregulation of D~2~ function (D~2~ hypersensitisation) ([@bibr166-0269881116654697]), the same mechanism thought to be responsible for supersensitivity psychosis, although manifested in the motor function domain, not in the emotion and cognition domains. This distinction between TD and supersensitivity psychosis may be due to regional differences in D~2~ upregulation, with TD strongly associated with changes in the dorsal striatum, while supersensitivity psychosis with changes in the ventral striatum (including the nucleus accumbens) ([@bibr28-0269881116654697]). Recently, the emphasis is shifted to the drug-induced synaptic plasticity in cortico-striatal transmission in the striatum. It is suggested that the synaptic plasticity is maladaptive, resulting in an imbalance between direct and indirect pathways in the striatum, and leads to perpetuating abnormal movements even after drug withdrawal ([@bibr84-0269881116654697]). Other ideas such as drug-induced disturbances of oxidative stress response systems and impacts on serotonin receptors and GABAergic medium spiny neurons have also been proposed ([@bibr11-0269881116654697]). Regardless of the precise mechanisms, TD is a cluster of persistent abnormal movement syndromes associated with long-term treatment with antipsychotic drugs. With its strong developmental feature, it likely reflects an increase of motor impairment effects of certain antipsychotic drugs, a type of antipsychotic sensitization.

Other phenomena {#section8-0269881116654697}
---------------

Other forms of antipsychotic sensitization and tolerance have been reported. For example, [@bibr178-0269881116654697] studied the time-based sensitization of cognitive impairment with haloperidol. They gave 24 healthy male subjects placebo on Day 1 and haloperidol (2 mg) on Days 2 and 25 and tested their cognitive function before dosing, and over a 24-hour period after dosing on Days 1, 2, and 25. They observed a clear impairment of cognitive function at 6--8 h after administration of haloperidol on Day 2. More importantly, when a single-dose of haloperidol was given again 25 days later, a greater level of impairment with earlier onset was noted in several tests in both treatment groups, indicating an antipsychotic sensitization effect. On the other hand, clozapine tolerance has been observed in some patients treated with clozapine. They show withdrawal symptoms (e.g. nausea, vomiting, insomnia, diarrhea, agitation, aggression, headache, etc.) ([@bibr164-0269881116654697]) and relapse to psychosis ([@bibr138-0269881116654697]), often seen with the discontinuation of clozapine use.

Overall, clinical studies have identified several clinical phenomena indicative of antipsychotic sensitization (e.g. exponential time course of symptom improvement, TDS, and TD) and antipsychotic tolerance (e.g. supersensitivity psychosis, clozapine withdrawal symptoms). However, most of them are descriptive and not mechanistic-oriented. After reviewing some recent clinical studies on antipsychotic tolerance, [@bibr46-0269881116654697] concluded that "it seems highly likely that all antipsychotic treatments induce clinically important neuroadaptations during chronic drug administration, although the nature of such neuroadaptations remains unclear." The possible distinctive neuroadaptations associated with sensitization and tolerance effect have not been explored. [@bibr145-0269881116654697] conducted a retrospective review of neuroleptic dosages over a five-year period in 19 chronic schizophrenic patients. They found that some patients developed tolerance, while others developed sensitization, as indicated by their consistent yearly increases or decreases in dosage, suggesting that individual factors are also important in determining the direction of change in drug sensitivity. Unfortunately, it is not clear what the important pharmacological and dispositional factors are that influence these individual differences. Furthermore, the theoretical framework adequate to explain antipsychotic sensitization and tolerance is lacking. In the following, we will turn to preclinical animal work which in some way addressed these issues.

Preclinical evidence for antipsychotic-induced behavioral sensitization and tolerance {#section9-0269881116654697}
=====================================================================================

Sensitization and tolerance induced by antipsychotic drugs have a long research history. The first report of antipsychotic tolerance in English that can be found on the PubMed database is a study by [@bibr21-0269881116654697] who reported that Wistar rats developed tolerance to the motor suppressant and lethal effects of chlorpromazine over a period of 40 weeks when they were injected with increasing daily doses of chlorpromazine. [@bibr150-0269881116654697] also reported that tolerance occurred to repeated dosing with clozapine (2.5--20 mg/kg, p.o) and thioridazine (5--20 mg/kg, p.o), but not to haloperidol or perphenazine in locomotor activity in mice. At the end of the 19 days of drug administration, clozapine, and thioridazine even caused an increase in locomotor activity, a sign of behavioral supersensitivity ([@bibr137-0269881116654697]). On sensitization, [@bibr9-0269881116654697] reported that a single injection of low, clinically relevant doses of haloperidol and fluphenazine hydrochloride causes catalepsy in rats that grows over time "such that one re-exposure to the same compound up to 8 weeks later results in a marked enhancement (i.e. sensitization) of this response."

Over the years, many preclinical studies provide strong support for chronic antipsychotic-induced sensitization and tolerance ([@bibr9-0269881116654697]). For example, intermittent haloperidol treatment via daily injection is shown to cause a progressively potentiated catalepsy ([@bibr6-0269881116654697]), enhanced vacuous chewing movements (VCMs, a proxy for tardive dyskinesia in humans) over time ([@bibr166-0269881116654697]), enhanced suppression of milk intake ([@bibr179-0269881116654697]), enhanced disruption of conditioned avoidance responding (CAR) ([@bibr80-0269881116654697]), enhanced impairment of reward-based lever pressing rates ([@bibr165-0269881116654697]; [@bibr169-0269881116654697]), enhanced disruption of maternal behavior ([@bibr183-0269881116654697]), and enhanced inhibition of phencyclidine (PCP)-induced hyperlocomotion ([@bibr153-0269881116654697]). A similar effect on the PCP-induced hyperlocomotion has also been found with repeated clozapine and olanzapine treatment ([@bibr153-0269881116654697]). In addition, repeated clozapine treatment is also shown to induce increasing numbers of myoclonic seizure-like jerks in rats ([@bibr147-0269881116654697]). Finally, [@bibr53-0269881116654697] demonstrated sensitization for the rate-suppressing effects of the typical antipsychotic pimozide.

With regards to the antipsychotic-induced tolerance, continuous haloperidol treatment via osmotic mini-pump has been shown to cause a progressively decreased inhibition of spontaneous motor activity in rats ([@bibr24-0269881116654697]), increased behavioral supersensitivity, as measured by increased amphetamine-induced locomotor activity following antipsychotic discontinuation ([@bibr127-0269881116654697]), and a progressively decreased disruption of avoidance responding over time ([@bibr126-0269881116654697]). [@bibr146-0269881116654697] reported that clozapine-treated rats exhibited tolerance to the drug's suppressive effect on the amount of time that rats were in contact with a force-sensing target disk. [@bibr165-0269881116654697] found that repeated injections of clozapine, but not haloperidol enhanced its suppression of lever pressing in a fixed ratio 5 (FR-5, 5 presses result in one reward). Porter and colleagues have conducted a series of experiments to identify differences between the acute and subchronic effects of antipsychotic drugs on operant responding in rats. In one earlier study, they demonstrated that acute treatment with clozapine significantly suppressed operant response rates on fixed-interval 60-second responding. With repeated drug administration and testing, the clozapine-treated rats gradually developed tolerance to the drug effects and recovered back to the vehicle control levels after seven days of drug treatment ([@bibr53-0269881116654697]). Later, their group reported that although acute clozapine (10 mg/kg) significantly disrupted response rates and reinforcement rates and significantly increased response duration on a schedule of multiple random interval responding for food reinforcement, chronic administration of clozapine resulted in a development of tolerance ([@bibr171-0269881116654697]). [@bibr169-0269881116654697] also found that repeated clozapine produced a decrease in the rate of responding for food reward under a multiple FR 30/ fixed-interval (FI) 60-second schedule. More importantly, the degree to which clozapine tolerance develops appears to depend in part on the schedule of reinforcement, with more complete tolerance observed under a FI 60-second schedule ([@bibr53-0269881116654697]), and only partial tolerance (approximately 50--75%) under a FR 30 schedule ([@bibr169-0269881116654697]; [@bibr171-0269881116654697]). This differential tolerance was attributed to the different baseline levels of responding generated by these reinforcement schedules ([@bibr169-0269881116654697]). Clozapine-induced tolerance has also been observed in a drug discrimination task ([@bibr47-0269881116654697]) and rat maternal behavior ([@bibr183-0269881116654697]). Taken together, antipsychotic sensitization and tolerance appear to be inevitable features associated with repeated drug treatment. Therefore, understanding the neurobiological and behavioral factors that modulate the induction and expression of sensitization/tolerance is expected to greatly enhance our understanding of the effects of clinical treatment.

As mentioned above, antipsychotic sensitization refers to the increased behavioral responsiveness to an antipsychotic drug due to past drug treatment history, while tolerance refers to the opposite behavioral pattern (i.e. decreased responsiveness). In recent years, we developed a two-phase paradigm to study antipsychotic sensitization and tolerance. In the *induction phase*, different groups of animals are being repeatedly treated with various doses of an antipsychotic drug or vehicle for 3--7 days and tested in a behavioral model of antipsychotic activity (e.g. the conditioned avoidance response model) daily. In the *expression phase*, all animals are being challenged with a single dose of the drug and their performance in the test is compared. The magnitude of antipsychotic sensitization and tolerance can be measured in two ways in both phases ([@bibr113-0269881116654697]; [@bibr155-0269881116654697]), similar to the ones used in the behavioral sensitization induced by psychostimulants ([@bibr22-0269881116654697]). The first index of antipsychotic sensitization or tolerance is revealed through a within-subjects comparison in the induction phase during which the behavioral effect of the drug is either stronger or weaker on the last day of drug treatment than that on the first day (e.g. a comparison between days 1 vs 5) ([@bibr180-0269881116654697]). A second index is derived from a between-subjects comparison in the expression phase during which the behavioral responses of drug-pretreated and vehicle-pretreated animals are compared. With a between-groups analysis, antipsychotic sensitization or tolerance is indicated if drug-pretreated animals show a significantly greater or lower sensitivity to the drug challenge than vehicle-pretreated animals. Overall, it is believed that a between-subjects analysis provides a more "conservative" index of sensitization or tolerance ([@bibr22-0269881116654697]), as this approach ensures that variables that could contribute to potential changes in behavior are present in both the drug and vehicle control groups. In some cases, the behavior affected by an antipsychotic drug (as an index of antipsychotic effect) is allowed to recover under the drug-free condition to the pre-drug and vehicle control level before the drug challenge, thus, any group difference found on the challenge test could only be attributed to past drug treatment history. This approach provides the strongest demonstration of antipsychotic sensitization and tolerance. [Figure 1](#fig1-0269881116654697){ref-type="fig"} illustrates such an approach in the conditioned avoidance response test of antipsychotic drugs.

![A schematic depiction of the two-phase paradigm used to study antipsychotic sensitization and tolerance. In the induction phase, different groups of animals are being repeatedly treated with various doses of an antipsychotic drug or vehicle for 3--7 days and tested in a behavioral model of antipsychotic activity daily. Antipsychotic sensitization or tolerance is revealed through a within-subjects comparison in this phase during which the behavioral effect of the drug is either stronger or weaker on the last day of drug treatment than that on the first day. In the expression phase, all animals are being challenged with a single dose of the drug and their performance in the test is compared. Antipsychotic sensitization or tolerance is indicated if drug-pretreated animals show a significantly greater or lower sensitivity to the drug challenge than vehicle-pretreated animals.](10.1177_0269881116654697-fig1){#fig1-0269881116654697}

It is well established that at clinically relevant doses, all clinically approved antipsychotic drugs acutely suppress avoidance responding without altering unconditioned escape response in rats ([@bibr12-0269881116654697]; [@bibr176-0269881116654697]). Thus, the magnitude of avoidance suppression is frequently used as a validated behavioral index of antipsychotic activity ([@bibr12-0269881116654697]; [@bibr19-0269881116654697]; [@bibr139-0269881116654697]; [@bibr168-0269881116654697]; [@bibr175-0269881116654697]). As [Figure 1](#fig1-0269881116654697){ref-type="fig"} shows, in the induction phase, antipsychotic sensitization or tolerance in this test is observed when the avoidance-disruptive effect of the drug increases or decreases in magnitude throughout the treatment period. In the expression phase, sensitization or tolerance is shown when the drug-treated animals exhibit a lower or higher avoidance response than those treated with vehicle ([@bibr81-0269881116654697]). Several early studies have demonstrated both effects in the conditioned avoidance response test. For example, [@bibr36-0269881116654697] found that the anti-avoidance effect of haloperidol started on the first testing day and was progressively enhanced with each subsequent drug administration (across-session decline in avoidance responding). It reached a maximum level within 5--8 days. [@bibr71-0269881116654697] and [@bibr18-0269881116654697] confirmed this finding and extended it to two other classes of antipsychotics, YM-08050, YM-08051 and pimizode respectively. Using a home-cage control group injected with drugs but not tested repeatedly for avoidance responding, they also showed that the across-session decline in avoidance responding was not due to the accumulation of the drugs with repeated dosing. [@bibr129-0269881116654697] showed that repeated administration of clozapine over four days induces a strong tolerance to the avoidance-disruptive effect of clozapine. It should be noted that many previous studies on antipsychotic sensitization and tolerance have not paid enough attention to the distinct processes of the induction and expression. Most of them only focused on the induction process. [Figure 2](#fig2-0269881116654697){ref-type="fig"} shows the results of haloperidol sensitization in the conditioned avoidance response model in adult rats ([@bibr155-0269881116654697]). The sensitization pattern is clearly demonstrated in both phases.

![(a) Effect of repeated haloperidol (HAL) treatment (0.025 mg/kg, sc, -60 min) on conditioned avoidance responding across sessions. Number of avoidance responses made by the rats on the final training day (drug-free), five days of drug exposure and two drug-free retesting sessions are expressed as mean+standard error of the mean (SEM). Rats received either 0, 1, 2, 3, 4, or 5 days of HAL according to their group, \**p*\<0.05. (b) Effect of number of drug exposure days on final challenge day. All groups were injected with HAL (0.025 mg/kg) and avoidance responses were measured, \**p*\<0.05. Adapted from [@bibr155-0269881116654697] Parametric studies of antipsychotic-induced sensitization in the conditioned avoidance response model: Roles of number of drug exposure, drug dose, and test-retest interval. *Behav Pharmacol* 23: 380--391 with permission from Wolters Kluwer Health, Inc.\
VEH: vehicle; SC: subcutaneously; -60 min: 60 min before test.](10.1177_0269881116654697-fig2){#fig2-0269881116654697}

Similarly, it is possible to apply this basic paradigm to other behavioral tests of antipsychotic drugs. For example, the same paradigm has been used to demonstrate that repeated administration of olanzapine (also, risperidone, asenapine) or clozapine induces a potentiated (sensitization) or a decreased (tolerance) inhibition of the PCP-induced hyperlocomotion, respectively ([@bibr34-0269881116654697]; [@bibr113-0269881116654697]; [@bibr153-0269881116654697]; [@bibr180-0269881116654697]; [@bibr184-0269881116654697]), another preclinical test for antipsychotic activity ([@bibr44-0269881116654697]) (see [Figure 4(a)](#fig4-0269881116654697){ref-type="fig"}). Furthermore, this paradigm could also be used to conduct cross-sensitization or cross-tolerance studies by challenging animals with a different antipsychotic drug during the expression phase. As an example, [@bibr181-0269881116654697] shows that rats previously treated with risperidone in the induction phase showed stronger reactivity to the avoidance-disruptive effect of olanzapine administered in the expression phase. Recently, a cross-sensitization from asenapine to olanzapine in both the conditioned avoidance response model ([Figure 3](#fig3-0269881116654697){ref-type="fig"}) and the PCP-induced hyperlocomotion model ([Figure 4](#fig4-0269881116654697){ref-type="fig"}) has also been observed ([@bibr113-0269881116654697]).

![Prior asenapine (ASE) treatment increased sensitivity to ASE re-exposure and olanzapine (OLZ) exposure in the avoidance response. (as) Number of avoidance responses in the ASE (0.10 mg/kg) challenge test; (b) OLZ (0.50 mg/kg) challenge test and (c) clozapine (CLZ, 2.50 mg/kg) challenge test is expressed as mean+standard error of the mean (SEM), \**p*\<0.05, \*\**p*\<0.01 relative to the vehicle (VEH) group; \#*p*\<0.05 relative to the ASE 0.05 group. Adapted from [@bibr113-0269881116654697] Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity. *Neuropharmacology* 75C: 356--364 with permission from Elsevier.](10.1177_0269881116654697-fig3){#fig3-0269881116654697}

![Prior asenapine (ASE) treatment increased the inhibition of PCP-induced hyperlocomotion upon asenapine re-exposure and on olanzapine (OLZ) and clozapine (CLZ) treatment in adult rats. (a) Locomotor activity was measured for 60 min after vehicle (for the vehicle (VEH)+VEH-1 group) or PCP (3.20 mg/kg, sc, for the other five groups) injection and expressed as mean+standard error of the mean (SEM) for each group. ASE (0.10 mg/kg, sc) was injected 30 min before the vehicle or PCP injection. (b) Locomotor activity was measured for 60 min after vehicle or PCP injection and expressed as mean+SEM for each group. OLZ (0.50 mg/kg, sc) was injected 30 min before the vehicle or PCP injection. (c) Locomotor activity was measured for 60 min after vehicle or PCP injection and expressed as mean+SEM for each group. CLZ (2.50 mg/kg, sc) was injected 30 min before the vehicle or PCP injection. (*n*=8/group). Both the VEH+VEH-1 and VEH+VEH-2 groups were repeatedly injected with 0.9% saline for five consecutive days in the induction phase. The only difference was that on the challenge test days, the VEH+VEH-1 group was injected with ASE/OLZ/CLZ followed by another saline injection, whereas the VEH+VEH-2 group was injected with ASE/OLZ/CLZ followed by a PCP injection. \*\**p*⩽0.001 relative to VEH+VEH-1 group; \#*p*\<0.05, \#\#*p*≤0.001 relative to VEH+VEH-2; &*p*\<0.05, &&*p*⩽0.004 relative to VEH+PCP; \$*p*\<0.05, \$\$*p*⩽0.009 relative to ASE 0.20+PCP group. Adapted from [@bibr113-0269881116654697] Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity. *Neuropharmacology* 75C: 356--364 with permission from Elsevier.\
PCP: phencyclidine.](10.1177_0269881116654697-fig4){#fig4-0269881116654697}

Factors that influence antipsychotic sensitization and tolerance {#section10-0269881116654697}
================================================================

It is common knowledge that both pharmacological factors (e.g. dose, schedule, and route of drug administration, presence of other drugs, etc.) and nonpharmacological factors (e.g. environmental stimuli, selected behavioral responses, passage of time, etc.) affect the development of behavioral sensitization and tolerance induced by psychoactive drugs ([@bibr30-0269881116654697]). Behavioral sensitization and tolerance induced by antipsychotic drugs are no exceptions. This section selectively reviews relevant reports, illustrating the principles of how these two classes of factors exert their impacts on the induction and expression of antipsychotic sensitization and tolerance.

Pharmacological factors {#section11-0269881116654697}
-----------------------

### Drug dose {#section12-0269881116654697}

Antipsychotic sensitization and tolerance are dependent upon a number of factors including dose and number of exposures. In fact, it is well known that drug doses can even determine whether a sensitization effect or tolerance effect will be observed. The general observation is that a sensitization is likely to occur if a low dose is being used, whereas a tolerance often results from a treatment with a higher dose. For instance, haloperidol at low and medium doses in rats (e.g. 0.25 mg/kg) cause a sensitization in a catalepsy test ([@bibr68-0269881116654697]), at high doses (e.g. 1.0 mg/kg) it tends to cause a tolerance ([@bibr31-0269881116654697]; [@bibr107-0269881116654697]). Similarly, clozapine at the high and medium doses (e.g. 5.0 to 10.0 mg/kg) causes a tolerance but at low doses (e.g. 1.0 mg/kg) cause a sensitization ([@bibr147-0269881116654697]). Thus, sensitization or tolerance may not be an intrinsic feature of any particular drug or its particular behavioral effect, but is modulated by drug dose.

Within a dose range that typically induces either a sensitization or tolerance, the higher the dose, the stronger the sensitization or tolerance effect. This conclusion was recently demonstrated in the conditioned avoidance response test. [@bibr155-0269881116654697] tested three doses of haloperidol (0.025, 0.05 and 0.10 mg/kg) and three doses of olanzapine (0.5, 1.0 and 2.0 mg/kg) using the two-phase paradigm. Rats were first repeatedly treated with haloperidol or olanzapine for three consecutive days and tested for avoidance response. Three days later, all of them were challenged with haloperidol or olanzapine. Haloperidol or olanzapine at the low dose was unable to induce a long-term sensitization as assessed in the expression phase. In contrast, the medium or high doses induced robust sensitization with just three days of drug treatment. Similarly, [@bibr34-0269881116654697] showed that clozapine tolerance is dose-dependent, as a higher dose (e.g. 10 mg/kg) induces a stronger tolerance than that induced by a lower one (2.5 or 5.0 mg/kg).

### Number of drug administrations {#section13-0269881116654697}

Antipsychotic-induced sensitization and tolerance have drug memory-like property. From the learning and memory perspective, the induction and expression phases can be characterized as the training (i.e. acquisition) and memory testing phases. The number of drug injections can thus be conceptualized as the number of learning trials (sessions). Therefore, it is expected that the strength of antipsychotic sensitization and tolerance will be more prominent following a greater number of drug injections. In one study ([@bibr81-0269881116654697]), rats that were treated with olanzapine (1.0 mg/kg) for 3 days displayed a relatively less robust sensitization effect than those who were treated with the drug for 5-7 days in other studies ([@bibr74-0269881116654697]; ([@bibr75-0269881116654697]; [@bibr87-0269881116654697]). [@bibr155-0269881116654697] compared 5 groups of rats that received 1 to 5 days of drug administration and found that sensitization induced by haloperidol (0.025 mg/kg) or olanzapine (0.5 mg/kg) was only apparent in rats that received injections for 5 days. The groups that had 1 to 4 days of injections did not even have slightly lower avoidance levels on the challenge day; instead, their levels were no different from that of the vehicle control group. These results suggest that antipsychotic sensitization is dependent on the number of drug exposures, with more exposures leading to a stronger sensitization effect.

### Drug dosing regimen {#section14-0269881116654697}

Previous work suggests that drug dosing regimens determine many features of long-term treatment outcomes, with an intermittent and transient treatment (e.g. daily injection) tending to cause a sensitization effect while a continuous treatment (e.g. osmotic minipump) causes a tolerance ([@bibr115-0269881116654697]). Indeed, it has been shown that continuous haloperidol or olanzapine exposure to rats via osmotic minipump caused a greater increase in VCMs (a proxy for tardive dyskinesia in humans) than transient subcutaneous injections ([@bibr167-0269881116654697]). Similarly, continuous haloperidol treatment caused an attenuated disruption (tolerance) of avoidance responding (a measure of antipsychotic activity), while intermittent haloperidol treatment potentiated avoidance disruption (sensitization) ([@bibr127-0269881116654697], [@bibr126-0269881116654697]). Recently, we also demonstrated that haloperidol sensitization induced throughout adolescence in the conditioned avoidance response test persisted into adulthood only when haloperidol was administered via daily injection. If haloperidol was administered via osmotic minipump, the sensitization effect was not apparent ([@bibr38-0269881116654697]). This differential response to intermittent versus continuous treatment probably reflects differential effects of antipsychotic drugs on dopamine systems, especially on postsynaptic D~2~ receptors ([@bibr127-0269881116654697]).

### Drug-drug interactions {#section15-0269881116654697}

Most patients with schizophrenia are being treated with multiple psychotherapeutic drugs, such as antipsychotics, SSRIs and benzodiazepines in order to control their diverse symptoms and co-morbid anxiety and depression ([@bibr185-0269881116654697]). This practice of psychotropic polypharmacy has raised some concerns regarding the efficacy, costs and possible adverse effects of drug-drug interactions (DDIs) ([@bibr4-0269881116654697]; [@bibr124-0269881116654697]; [@bibr128-0269881116654697]). However, because current clinical data come mostly from case reports and limited uncontrolled studies, it is difficult to assess the extent and nature of DDIs and determine how antipsychotic sensitization or tolerance might be altered by DDIs. A few years ago, a drug-drug conditioning paradigm was developed to examine how concurrent use of chlordiazepoxide with haloperidol or olanzapine might affect the induction and expression of antipsychotic sensitization in the conditioned avoidance response test ([@bibr76-0269881116654697]). It was observed that pairing of chlordiazepoxide with haloperidol during the repeated drug test phase for seven days attenuated the anti-avoidance effect of haloperidol, indicating an attenuation of the development of haloperidol sensitization. However, such pairing did not have a lasting effect on the expression of haloperidol sensitization, as there was no group difference between the group that received the chlordiazepoxide+haloperidol pairing and those that received no such pairing in the haloperidol challenge test. In contrast, pairing of chlordiazepoxide with olanzapine had little effect on the induction of olanzapine sensitization, but did reduce its expression. This effect of chlordiazepoxide is due to drug-drug conditioning, as the control groups that received the same treatment (i.e. chlordiazepoxide with haloperidol or olanzapine) but separated by 24 h did not show such an effect. These findings suggest that concurrent use of chlordiazepoxide with antipsychotics, especially with olanzapine, may cause a long-term attenuation of olanzapine sensitization through a drug-drug interaction mechanism.

Following a similar approach, a recent study examined how the antidepressant citalopram pairing with haloperidol or olanzapine during the induction phase affects antipsychotic sensitization in the conditioned avoidance response model ([@bibr144-0269881116654697]). It was reported that concurrent use of citalopram with both antipsychotic drugs potentiated the anti-avoidance effect of olanzapine or haloperidol (to a lesser extent) during the seven drug test sessions, indicating that citalopram enhanced the development of antipsychotic sensitization. However, in the subsequent challenge test, no group difference was found, suggesting that repeated pairing of citalopram with haloperidol or olanzapine did not affect the expression of antipsychotic sensitization. These findings suggest that the presence of an antidepressant could potentially change the strength of antipsychotic sensitization, and possibly the antipsychotic efficacy of haloperidol and olanzapine in the treatment of schizophrenia. Recently, we observed that concurrent nicotine treatment attenuated haloperidol's sensitized effect on avoidance response (unpublished observation). This finding also suggests that haloperidol sensitization might involve drug-induced changes in nicotinic receptor. It has been reported that haloperidol non-competitively inhibits the function of mammalian neuronal nicotinic α4β2 and α7 receptors with potencies comparable to that of mecamylamine (a classical nicotinic receptor antagonist) ([@bibr49-0269881116654697]).

Nonpharmacological factors {#section16-0269881116654697}
--------------------------

Like behavioral sensitization and tolerance induced by other psychoactive drugs such as amphetamine ([@bibr22-0269881116654697]) and morphine ([@bibr142-0269881116654697]), antipsychotic sensitization and tolerance are also greatly affected by nonpharmacological factors such as environmental stimuli, selected behavioral responses, behavioral testing contingencies, and passage of time, etc.. In the following, I will summarize some relevant work on this topic.

### Environmental cues and selected behavioral responses {#section17-0269881116654697}

It is well established that the manifestations of behavioral sensitization and tolerance induced by many psychoactive drugs are not mere consequences of the pharmacological actions of the drugs, but are the result of interactions amongst the pharmacological effects of drugs and the environmental cues during drug administration. The importance of environmental factors in modulating antipsychotic sensitization and tolerance has been demonstrated by many investigators. The typical approach is to compare a "paired" group (a group that receives drug injection in the test environment) with an "unpaired" group (a group that receives vehicle injection in the test environment, and drug in the home cage) ([@bibr6-0269881116654697]; [@bibr107-0269881116654697]). The influence of environment is assessed on a test day, when all animals receive a challenge injection of the drug in the test environment. If a stronger or weaker drug effect is detected in the "paired" group, it would suggest that environmental stimuli have an influence on the drug effect ([@bibr122-0269881116654697]). Using such an approach, [@bibr107-0269881116654697] demonstrated that Pavlovian conditioning factors determine the expression of tolerance to haloperidol catalepsy. They found that rats exhibited tolerance only in the environment previously associated with haloperidol injections, but not in the environment previously associated with saline injections. In addition, a drug-induced increase in the number of brain dopamine receptors, by itself, cannot account for the conditional occurrence of such tolerance. Schmidt's group reported that intermittent haloperidol treatment and repeated catalepsy testing caused a sensitized cataleptic response over time and this sensitization was completely context specific, since context changes abolished catalepsy sensitization ([@bibr6-0269881116654697]; [@bibr68-0269881116654697]). They reported that rats treated with haloperidol (0.25 mg/kg, i.p.) and tested over a nine-day period showed intensification of catalepsy. However, when the rats were tested in another environment, this change of the environmental context abolished the catalepsy sensitization. In addition, they found that rats that were treated with haloperidol in the home cages but not repeatedly tested for catalepsy also did not show catalepsy sensitization; often they developed tolerance towards the cataleptogenic effects of haloperidol ([@bibr130-0269881116654697]). Similarly, sensitization induced by haloperidol and olanzapine in the conditioned avoidance response test was also context dependent, as only the rats treated with both drugs in the avoidance test apparatus and tested for avoidance responding exhibited such a sensitization; those that received the identical treatments in the home cages did not ([@bibr76-0269881116654697]; [@bibr144-0269881116654697]).

Recently, a different approach was employed to examine the context-dependent sensitization and tolerance. It takes advantage of the fact that repeated antipsychotic treatment induces sensitization or tolerance in both the conditioned avoidance response and PCP-induced hyperlocomotion models, and sensitization or tolerance induced in these two models presumably reflects the same antipsychotic activity over time. If antipsychotic sensitization or tolerance results from inevitable neurobiological adaptations produced by the direct pharmacological actions of the drug ([@bibr160-0269881116654697]), it should be transferrable across models and suggests that contextual and behavioral variables have little influence on the development of antipsychotic sensitization or tolerance. On the other hand, if context and behaviors associated with drug administration have a powerful control on the expression of antipsychotic sensitization or tolerance, it should not be transferrable between models. In the first study ([@bibr180-0269881116654697]), we tested haloperidol and olanzapine sensitizations and examined their bi-directional transfer between the conditioned avoidance response model and PCP model. Results showed that haloperidol and olanzapine sensitization induced in both models only manifested itself when the induction model was the same as the expression model. There was no expression of such a sensitization effect when the tested environment and required behavioral response were different from the original ones. These findings suggest the expression of haloperidol and olanzapine sensitization in the conditioned avoidance response model and PCP model is strongly influenced by test environment and/or selected behavioral response ([@bibr180-0269881116654697]).

[@bibr34-0269881116654697] used a similar approach and examined how the environmental cues and behavioral responses affect the expression of clozapine tolerance. They found that when tested in the PCP model, rats previously treated with clozapine in the avoidance model did not show an immediate weaker inhibition of PCP-induced hyperlocomotion than those treated with clozapine for the first time, but showed a significantly weaker inhibition over time, suggesting that switching the environments diminished the initial expression of clozapine tolerance. In contrast, when tested in the avoidance response model, rats previously treated with clozapine in the PCP model showed an immediate weaker disruption of avoidance response than those treated with clozapine for the first time, but this weaker effect reduced over time. Therefore, similar to antipsychotic sensitization, the expression of clozapine tolerance is also strongly modulated by the test environment and/or selected behavioral response.

Because the context-dependent feature of antipsychotic sensitization and tolerance resembles the one found in psychomotor sensitization ([@bibr7-0269881116654697]; [@bibr8-0269881116654697]; [@bibr22-0269881116654697]; [@bibr122-0269881116654697]; [@bibr149-0269881116654697], [@bibr170-0269881116654697]), and tolerance ([@bibr108-0269881116654697]; [@bibr142-0269881116654697]; [@bibr143-0269881116654697]), the theoretical conceptualization of antipsychotic sensitization and its situational specificity can gain insights from the theoretical accounts of behavioral sensitization and tolerance. Based on the present study, our previous work ([@bibr79-0269881116654697], [@bibr80-0269881116654697], 2009, [@bibr76-0269881116654697], [@bibr81-0269881116654697], [@bibr87-0269881116654697]) and the work of others ([@bibr8-0269881116654697]; [@bibr149-0269881116654697]), we propose that three psychological processes may govern the effect of antipsychotic sensitization or tolerance and its situational specificity ([@bibr180-0269881116654697]): (a) repeated antipsychotic treatment induces an unconditioned and nonassociative increase or decrease of behavioral effects (i.e. sensitization); an effect attributable to the direct pharmacological action of a drug, likely mediated by drug-induced time-dependent brain changes involving various receptors or other molecules that antipsychotic drugs target; (b) distinct contextual cues (e.g. environmental stimuli, interoceptive drug cue, etc.) develop an association with unconditional drug effects via a Pavlovian conditioning process and thus become excitatory conditioned stimuli. These cues acquire the ability to elicit an antipsychotic-like effect by themselves, and may potentiate the sensitized or diminished response in an expected situation; (c) situational cues, including the contextual stimuli, interoceptive drug state, as well as topographic difference in motor responses, serve as occasion-setters to modulate the manifestation of altered responses. Occasion-setters are a class of conditional stimuli that do not themselves elicit an antipsychotic-like effect, but modulate the ability of other stimuli to elicit responses ([@bibr51-0269881116654697]). According to this hypothesis, the same situational cue could function as both a drug-like CS and an occasion-setter.

At last, we would to emphasize that there are not two forms of antipsychotic sensitization or tolerance: "context-specific" and "context-independent", just as there are not two forms of behavioral sensitization induced by psychostimulants ([@bibr8-0269881116654697]). There is just one non-associative form of neuroplasticity manifesting behaviorally as an alteration in antipsychotic responses. This manifestation and its modulation by environmental cues and behaviors is dependent on specific experimental and drug treatment factors. Only under certain circumstances do environmental cues or behavioral responses modulate the development and expression of antipsychotic sensitization or tolerance. Therefore, the environmental cues and behavioral responses of animals may not fundamentally alter drug-induced neurobiological changes, say, in D~2~ or 5-HT~2A~ receptors. They only impact the functional manifestations of drug-induced brain changes. One recent study clearly illustrates this point because it demonstrates both the "context-dependent" and "context-independent" antipsychotic sensitization and tolerance for some drugs but not others and under one condition but not others ([@bibr154-0269881116654697]). In the first experiment, which examined the extent to which prior antipsychotic treatment in the home cages affected a drug's ability to inhibit PCP-induced hyperlocomotion in a novel motor activity test apparatus, it was shown that five days of repeated haloperidol and olanzapine treatment in the home cages still potentiated their inhibition of PCP-induced hyperlocomotion (i.e. the expression of antipsychotic sensitization) assessed in a new environment, whereas the clozapine treatment enhanced the development of clozapine tolerance. These findings indicate a lack of environmental modulation of antipsychotic efficacy, a finding different from [@bibr180-0269881116654697] and [@bibr34-0269881116654697]. The second experiment examined the impact of different numbers of antipsychotic administrations in either the home environment or test environment (e.g. 4, 2, or 0) on a drug's ability to inhibit PCP-induced hyperlocomotion. No environmental modulation was found for clozapine and olanzapine but a strong modulation was found for haloperidol, as evidenced by the finding that four-day haloperidol treatment in the test apparatus had a significantly higher inhibition than four-day home cage treatment. These findings collectively suggest that prior antipsychotic treatment in one environment could alter later antipsychotic-like response assessed in a different environment but only under certain test conditions. Therefore, whether the circumstances surrounding antipsychotic drug administration exert a powerful control of the expression of antipsychotic-like efficacy is dependent on many factors, including the degree of similarity between different test environments, drug doses, and number of drug treatments, etc. The environmental modulation on antipsychotic sensitization and tolerance may have a significant clinical implication. For one thing, it suggests that the environment where the drug is being administered could potentially change how a patient responds to the drug.

### Passage of time (i.e. test interval between the induction and expression phase) {#section18-0269881116654697}

Antipsychotic sensitization and tolerance likely reflect a composite impact from two sources. One is the relatively specific pharmacological actions of a given antipsychotic drug. As mentioned before, this is likely mediated by a drug's actions on its immediate neuroreceptor targets (e.g. D~2~ and 5-HT~2A~ receptors) ([@bibr81-0269881116654697]) and should follow the basic principles of learning and memory, as antipsychotic sensitization and tolerance represent a non-associative form of learning and memory. Under this principle, the magnitude of sensitization and tolerance should decrease with the passage of time due to a memory trace decay process (similar to forgetting). Another source is the ubiquitous adaptive response to the foreign aspect of the drug (any drug is an exogenous agent to an organism), which tends to follow the TDS principle ([@bibr9-0269881116654697], [@bibr10-0269881116654697]) and this response should increase with the passage of time upon acute exposure to the drug. Therefore, under one circumstance, we may see an increase of antipsychotic sensitization and tolerance when the experimental condition favors the TDS principle, whereas under other circumstances, the sensitization and tolerance effect may decrease when the forgetting force dominates. The ultimate intensity of antipsychotic sensitization or tolerance at any given time point likely reflects the consequence of a joint action from these two forces. An earlier study did not find that the magnitude of haloperidol and olanzapine sensitization in the conditioned avoidance response test changed across the three time intervals between the induction and expression phases (i.e. 4, 10, or 17 days after the last drug treatment) ([@bibr155-0269881116654697]). Recently, this issue was re-examined using 3 longer intervals (10, 20 and 40 days between the last drug treatment and challenge test) ([@bibr38-0269881116654697]). Once again, no increase or decrease in sensitization magnitude was observed at these test points. Thus, although theoretically, antipsychotic sensitization and tolerance could be a function of time, empirical evidence is lacking. Future research needs to examine the importance of different challenge doses and numbers of drug administration to determine the experimental conditions that favor TDS as it relates to antipsychotic sensitization and tolerance. In this regard, it appears that one single injection of haloperidol is able to induce a sensitization effect in the PCP-induced hyperlocomotion test and this effect is larger when assessed at the three-week post-injection point than at one-week post-injection (unpublished observation). We are actively pursuing this line of research to verify its robustness and its generality. It is also important to keep in mind that because environmental stimuli and behavioral response have a profound impact on the induction and expression of antipsychotic sensitization and tolerance (see the above discussion), in searching for the optimal condition that is conducive to TDS, we should pay more attention to the environmental cues and behavioral responses that are associated with drug administration.

Developmental impacts: Altered drug sensitivity due to adolescent drug exposure {#section19-0269881116654697}
===============================================================================

Antipsychotic treatment in children and adolescents has increased dramatically in recent decades ([@bibr55-0269881116654697]; [@bibr99-0269881116654697]; [@bibr114-0269881116654697]). Epidemiological surveys conducted in many countries (e.g. UK, US, Germany, Netherlands) indicate a two- to six-fold increase in the number of prescribed antipsychotics for young patients (⩽20 years) between the 1990s and the mid-2000s ([@bibr55-0269881116654697]; [@bibr99-0269881116654697]; [@bibr114-0269881116654697]). More than 90% of the children and adolescents who are treated with antipsychotic medications are on atypical drugs (e.g. risperidone, olanzapine, and aripiprazole) for the management of disruptive behavior disorders (37.8%), mood disorders (31.8%), pervasive developmental disorders, or mental retardation (17.3%) and psychotic disorders (14.2%) ([@bibr99-0269881116654697]). Clinical research on antipsychotic treatment in children and adolescents primarily focuses on the efficacy, tolerability, and side effect profiles of individual drugs. There is a general lack of research on the long-term consequences of adolescent antipsychotic treatment on the brain and the behavioral development of patients.

Preclinical studies strongly suggest that antipsychotic exposure in adolescence could alter brain and behavioral functions. For example, animal receptor binding studies show that antipsychotic exposure during adolescence increases or decreases various neuroreceptors, including dopamine D~1~, D~2~, and D~4~ receptors ([@bibr94-0269881116654697]; [@bibr172-0269881116654697]), serotonin 5-HT~1A~ and 5-HT~2A~ receptors ([@bibr26-0269881116654697]), and ionotropic NMDA and AMPA glutamatergic receptors ([@bibr25-0269881116654697]). Behavioral studies also suggest that early adolescent antipsychotic exposure enhances animals' sensitivity to reward stimuli ([@bibr172-0269881116654697]), impairs their working memory, delays the extinction process of fear memory in adulthood ([@bibr92-0269881116654697]), and prevents the development of various psychosis-like behaviors (e.g. prepulse inhibition (PPI) deficit, latent inhibition deficit, etc.) induced by maternal immune activation (PolyI:C injection during pregnancy), while impairing certain behavioral functions of normal animals ([@bibr91-0269881116654697]; [@bibr104-0269881116654697], [@bibr102-0269881116654697], [@bibr103-0269881116654697]).

In addition to the effects on basic brain and behavioral functions, adolescent antipsychotic exposure can also alter later antipsychotic responses in adulthood. Since 2012, we have conducted a series of experiments and delineated the extent to which antipsychotic exposure during adolescence affects 'exposure-dependent' alterations. Similar to what has been reported in adult animal studies, two patterns of alterations: sensitization and tolerance are also identified. The first study used the conditioned avoidance response model and addressed two important issues: first, whether olanzapine sensitization and clozapine tolerance can be induced in adolescent rats; second, the extent to which olanzapine sensitization and clozapine tolerance induced in adolescence persist into adulthood ([@bibr111-0269881116654697]). The basic paradigm is similar to that depicted in [Figure 1](#fig1-0269881116654697){ref-type="fig"}. Male adolescent rats (\~postnatal days (P) 43--47) were first treated with olanzapine or clozapine daily for five consecutive days and then challenged either in adolescence (\~P 50) or after they matured into adults (\~P 76 and 92). Olanzapine sensitization and clozapine tolerance were found in the behavioral measures of antipsychotic activity (e.g. avoidance response and intertrial crossing), but not in the measure of fear (e.g. CS-induced 22 kHz ultrasonic vocalizations (USVs)) ([@bibr88-0269881116654697]; [@bibr152-0269881116654697]). These findings suggest that antipsychotic treatment during adolescence can induce a long-term specific alteration in antipsychotic effect that persists into adulthood despite the brain maturation. Both olanzapine sensitization and clozapine tolerance effects are dose-dependent, specific to the antipsychotic effect (e.g. anti-avoidance), but not to the anxiolytic effect (e.g. a decreasing effect on 22-kHz USVs). These results also support the idea that the different behavioral effects of an antipsychotic drug undergo different time courses of change after repeated administration ([@bibr148-0269881116654697]).

Following this initial study, a series of studies have been conducted on other antipsychotic drugs. Risperidone, asenapine, and haloperidol are all found to cause a sensitization effect that persists into adulthood in a similar fashion as olanzapine in the conditioned avoidance response model ([@bibr39-0269881116654697]; [@bibr112-0269881116654697]; [@bibr140-0269881116654697]) (see [Figure 5](#fig5-0269881116654697){ref-type="fig"}). In addition, adolescent risperidone treatment could even alter adulthood responsiveness to olanzapine (a cross-sensitization effect) and clozapine ([@bibr112-0269881116654697]). Specifically, evidence indicates that adolescent risperidone treatment essentially enhances olanzapine sensitization and clozapine tolerance. These long-lasting changes are likely mediated by drug-induced neuroplastic changes and could have significant clinical implications because risperidone has been one of the most prescribed antipsychotic agents for children and adolescents ([@bibr100-0269881116654697]) and drug switching is quite common in people with schizophrenia during the course of optimizing therapeutic regimens for individual patients ([@bibr123-0269881116654697]). These findings suggest that the past history of a patient's experience with a given drug may impact his/her later response to a new drug. Thus, clinicians working with adult patients who have been treated with one drug (e.g. risperidone) but wish to switch to another drug (e.g. olanzapine or clozapine) may need to consider possible changes in antipsychotic efficacy and monitor patients' symptom response to the new drug during this switching process.

![Repeated asenapine (ASE) treatment increased the suppression of avoidance response in adolescent rats (postnatal days, P 43--48) (a) and increased sensitivity to ASE re-exposure in the challenge test in adulthood (P \~76) (b). Number of avoidance responses made by the rats from the ASE (0.05 mg/kg), ASE (0.10 mg/kg), ASE (0.20 mg/kg) and vehicle groups on the last training (pre-drug) day, during the five drug test days and on the challenge test day are expressed as mean+standard error of the mean (SEM). \*\**p*\<0.004, three ASE groups relative to the VEH group; \#*p*\<0.05, ASE 0.10 and ASE 0.20 groups relative to the ASE 0.05 group, respectively. Adapted from [@bibr141-0269881116654697] Asenapine sensitization from adolescence to adulthood and its potential molecular basis. *Behav Brain Res* 273: 166--176 with permission from Elsevier.\
VEH: vehicle.](10.1177_0269881116654697-fig5){#fig5-0269881116654697}

In order to validate the generality of adolescent antipsychotic sensitization and clozapine tolerance effects, it is necessary to employ a similar test paradigm used in one test (e.g., the conditioned avoidance response model) and apply it in another (e.g. PCP-induced hyperlocomotion model). [@bibr140-0269881116654697] did just that (see [Figure 6](#fig6-0269881116654697){ref-type="fig"}). This study showed that during adolescence, repeated olanzapine or clozapine treatment produced a persistent inhibition of PCP-induced hyperlocomotion across the five test days. In the challenge test during adolescence, rats previously treated with olanzapine did not show a significantly stronger inhibition of PCP-induced hyperlocomotion than those previously treated with vehicle. In contrast, those previously treated with clozapine showed a weaker inhibition than the vehicle controls. When assessed in adulthood, the enhanced sensitivity to olanzapine and the decreased sensitivity to clozapine were detected on \~P 76, even on \~P 91 in the case of olanzapine. These findings suggest that adolescent olanzapine or clozapine exposure can induce long-term alterations in antipsychotic response that persist into adulthood. A subsequent study demonstrated that repeated risperidone treatment in adolescence could also cause a sensitization effect in this model of antipsychotic activity ([@bibr110-0269881116654697]).

![Olanzapine (OLZ) sensitization from adolescence to adulthood. Locomotor activity was measured during the 60-minute test period after daily PCP injection throughout the five test days (left) and during the OLZ challenge test on postnatal day (P) 76 (right). OLZ at 1.0 and 2.0 mg/kg induced a sensitization effect in adulthood. Adapted from [@bibr140-0269881116654697] Adult response to olanzapine or clozapine treatment is altered by adolescent antipsychotic exposure: A preclinical test in the phencyclidine hyperlocomotion model. J *Psychopharmacol* 28: 363--375.\
VEH: vehicle; PCP: phencyclidine.](10.1177_0269881116654697-fig6){#fig6-0269881116654697}

Much of our adolescent antipsychotic sensitization and tolerance work has relied on a daily intermittent drug injection schedule for a short period of time (e.g. five days). How these long-term effects are modulated by treatment schedule has never been examined. In a recent study ([@bibr39-0269881116654697]), we explored how haloperidol sensitization induced throughout adolescence and tested in adulthood was differentially impacted by these two dosing regimens in the conditioned avoidance response test ([Figure 7](#fig7-0269881116654697){ref-type="fig"}). Adolescent rats were treated with haloperidol continuously (via osmotic minipump) or intermittently (via daily injection) from P 44 to 71. Haloperidol sensitization was assessed in a challenge test in adulthood (\>P 80) in which all rats were injected with haloperidol. Interestingly, only the intermittent dosing group showed a robust sensitization effect. This finding suggests that adolescent haloperidol sensitization is a schedule-specific phenomenon, much like what we observe in other behavioral effects of antipsychotic drugs ([@bibr126-0269881116654697]; [@bibr167-0269881116654697]). It is more likely to be seen under an intermittent dosing regimen than under a continuous dosing one.

![Effects of chronic continuous versus intermittent haloperidol (HAL) treatment on conditioned avoidance responding over time. (a) Number of avoidance responses made by the rats treated with HAL-0.25 CONT (0.25 mg/kg/day via minipump, *n*=14), HAL-0.05 INT (0.05 mg/kg/injection/day sc, *n*=14) or vehicle (VEH, *n*=13) on the predrug (0) day, and drug test days. \*\*\**p*\<0.001 for comparisons between HAL-(0.05 INT and 0.25 CONT) and vehicle (VEH); \#\#\#*p*\<0.001, \#\#*p*\<0.01, \#*p*\<0.05 for comparisons between HAL-0.05 INT and HAL-0.25 CONT on each test day. (b) Number of avoidance responses made by the three groups of rats in the HAL 0.05 mg/kg challenge tests. After retraining, all groups were injected with HAL 0.05 mg/kg (sc) 11 days after the last HAL treatment. Avoidance tests were conducted 60 min later. All data are expressed as mean+standard error of the mean (SEM). \*\**p*\<0.01 for comparison to the VEH group; \#\#*p*\<0.01 for comparison to the HAL-0.05 INT group. Adapted from [@bibr39-0269881116654697] Differential effects of intermittent versus continuous haloperidol treatment throughout adolescence on haloperidol sensitization and social behavior in adulthood. *Prog Neuropsychopharmacol Biol Psychiatry* 54: 67--75 with permission from Elsevier.\
CONT: continuous; INT: intermittent.](10.1177_0269881116654697-fig7){#fig7-0269881116654697}

Recently, we showed that persistent aripiprazole sensitization from adolescence to adulthood is sex-dependent (unpublished observation). In both the induction phase and the expression phase, male rats always had significantly lower avoidance than the females under aripiprazole, indicating that male rats might be more sensitive to aripiprazole treatment. This result suggests that antipsychotic sensitization might vary between sexes and clearly has a significant clinical implication if replicated.

As discussed at the beginning of this section, adolescent antipsychotic treatment is known to exert long-term impacts of basic behavioral and brain functions. However, no studies have examined whether adolescent antipsychotic treatment would affect social functioning in adulthood, one of seven primary cognitive domains that are affected in schizophrenia ([@bibr35-0269881116654697]; [@bibr48-0269881116654697],). [@bibr39-0269881116654697] examined how intermittent and continuous haloperidol treatment may potentially impact social interaction and social memory using a paradigm that we validated in amphetamine and phencyclidine-based animal models of schizophrenia ([@bibr77-0269881116654697]). The social memory of rats was evidenced by the findings that a subject rat decreased its time investigating the same testing partner after a waiting period (\~10 min) and increased its time on investigation if a novel partner was introduced ([@bibr3-0269881116654697]; [@bibr52-0269881116654697]; [@bibr109-0269881116654697],). Our results show that adolescent haloperidol treatment (continuous and intermittent) did not affect social behavior and social memory, as rats from the two haloperidol groups and the vehicle group exhibited a similar level of social interaction and showed a similar level of sensitivity to the change of social stimuli. This finding suggests that adolescent haloperidol treatment under both regimens did not fundamentally damage social functioning. Thus, the clinical significance of haloperidol sensitization needs to be further examined.

Collectively, these important findings firmly establish that antipsychotic treatment in adolescence can induce a long-term change in drug responsiveness that persists into adulthood. This altered sensitivity appears to be sex- and regimen-specific. Because antipsychotic drugs are being increasingly used in children and adolescents in the past two decades, findings from this study are important for understanding the impacts of adolescent antipsychotic treatment on the brain and behavioral developments. Furthermore, although we have demonstrated that environmental stimuli and behavioral response associated with drug treatment have a profound impact on the induction and expression of antipsychotic sensitization and tolerance in adult animals ([@bibr34-0269881116654697]; [@bibr154-0269881116654697]; [@bibr180-0269881116654697]), there is no study that has examined how such factors could affect adolescent antipsychotic sensitization and tolerance. Given their potential effects on brain development, if we can identify the clinical and experimental conditions that modulate adolescent antipsychotic sensitization and tolerance, we could then better use them to our advantages. This work also has implications for clinical practice involving adolescent antipsychotic treatments in terms of drug choice, drug dose, and schedule, and treatment setting.

Neurobiological mechanisms {#section20-0269881116654697}
==========================

Although behavioral sensitization and tolerance induced by antipsychotic drugs are well established, the molecular mechanisms (e.g. receptor, intracellular signaling molecules) and neural basis of these effects are less clear. Given the fact that all antipsychotic drugs have immediate actions on dopamine D~2~ and 5-HT~2A~ receptors ([@bibr90-0269881116654697]; [@bibr89-0269881116654697]; [@bibr93-0269881116654697]), and repeated antipsychotic treatment induces long-term changes in these receptors ([@bibr159-0269881116654697]), one naturally suspects that changes in these receptors may account for the behavioral sensitization and tolerance induced by antipsychotic drugs. As the following results may show, antipsychotic-induced changes in D~2~ and 5-HT~2A~ receptors in the various limbic areas are indeed in part involved in the mediation of the induction and/or expression of antipsychotic sensitization or tolerance. It should be noted that because many antipsychotics also have various degrees of affinity for a number of other neuronal receptors, including α-adrenergic, histamine H~1~, serotonin 5-HT~1A~, 5-HT~6~ and 5-HT~7~ receptors, and muscarinic receptors, and this multi-receptor action is likely to affect their efficacy and side effect profile ([@bibr82-0269881116654697]), the magnitude and persistence of antipsychotic sensitization and tolerance might also be, to some extent, modulated by these receptor-binding affinities. Unfortunately, there is little research on the involvement of receptors other than D~2~ and 5-HT~2A~ in antipsychotic sensitization and tolerance. Therefore, on the receptor mechanisms, we will have to limit ourselves to these two receptors.

Pharmacological studies on dopamine D~2~ and 5-HT~2A~ receptor mechanisms {#section21-0269881116654697}
-------------------------------------------------------------------------

[@bibr77-0269881116654697] took a pharmacological approach and compared the neuroreceptor mechanisms underlying acute and repeated treatment effects of haloperidol, clozapine, or olanzapine treatment, respectively. Specifically, they gave rats three days of repeated drug treatment and tested them in the conditioned avoidance response model. For some drug-treated rats, they were also concurrently administrated with either saline, quinpirole (a selective dopamine D~2/3~ agonist,), or 2,5-dimethoxy-4-iodo-amphetamine (DOI, a selective 5-HT~2A/2C~ agonist). After two days drug-free retraining, a drug challenge test was conducted to examine the magnitude of haloperidol/olanzapine sensitization and clozapine tolerance. A previous study already shows that acute pretreatment of quinpirole, but not DOI, can dose-dependently reverse the haloperidol-induced disruption of active maternal responses, whereas acute pretreatment of DOI, but not quinpirole can reverse the disruption induced by clozapine ([@bibr182-0269881116654697]). Based on these findings and the receptor binding profiles of each antipsychotic ([@bibr93-0269881116654697]), it was hypothesized that acute and repeated effects of haloperidol may be mediated by its action on D~2/3~ receptor system, whereas those of olanzapine and clozapine may be mediated by their action on 5-HT~2A/2C~ receptors. If this hypothesis were correct, quinpirole, but not DOI, should be able to attenuate acute haloperidol-induced disruption of avoidance response, and may also be effective in reducing haloperidol sensitization. In contrast, DOI, but not quinpirole, is expected to attenuate acute clozapine-induced disruption of avoidance, and may also be effective in reducing clozapine tolerance. For olanzapine, both quinpirole and DOI might have a reversal effect on its acute and repeated effects. This hypothesis was only partially confirmed. Specifically, pretreatment of quinpirole, but not DOI, did attenuate the acute haloperidol-induced disruption of avoidance responding and to a lesser extent, olanzapine-induced disruption. In contrast, pretreatment of DOI, but not quinpirole, attenuated the acute effect of clozapine. However, on the sensitization or tolerance effect, two unexpected findings were obtained. First, pretreatment of DOI, but not quinpirole, attenuated the haloperidol sensitization. Second, pretreatment of quinpirole enhanced the tolerance-like effect of clozapine and attenuated olanzapine sensitization. These results indicate that haloperidol sensitization may be mediated by its action on 5-HT~2A/2C~ receptor system, whereas long-term effects of olanzapine and clozapine may be mediated by their action on the D~2/3~ receptor system. Although haloperidol is typically viewed as a strong D~2~ antagonist, it is also a 5-HT~2A~ receptor inverse agonist ([@bibr177-0269881116654697]), and repeated haloperidol treatment causes a reduction in 5-HT~2A~ receptor mRNA expression in various limbic regions ([@bibr23-0269881116654697]). Therefore, it is possible that haloperidol causes a sensitization effect by down-regulating 5-HT~2A~ receptor. DOI may decrease this long-term impact of haloperidol by counteracting its effect on 5-HT~2A~ receptor. This idea is also consistent with the well-known augmentation effect of 5-HT~2A~ antagonism on the effects of haloperidol, as 5-HT~2A~-selective antagonist M100907 is shown to potentiate haloperidol-induced dopamine release in the medial prefrontal cortex ([@bibr20-0269881116654697]), to reduce the reward-attenuating effect of haloperidol ([@bibr16-0269881116654697]), and to potentiate the avoidance disruptive effect of haloperidol ([@bibr174-0269881116654697]). The clozapine tolerance and olanzapine sensitization via D~2/3~ receptor systems could be understood in the context of their known long-term effect on D~2/3~ receptors ([@bibr13-0269881116654697]; [@bibr63-0269881116654697]; [@bibr94-0269881116654697]). But why activation of D~2/3~ receptors reduces olanzapine sensitization but potentiates clozapine tolerance is not clear. One important lesson from this study is that the neuroreceptor mechanisms underlying the acute effect of an antipsychotic drug could be dissociable from those underlying its long-term effect. Thus, for the long-term effects such as sensitization and tolerance, the drug-initiated neural plasticity plays a more important role than the immediate targets of a drug.

Behavioral studies on dopamine D~2~ receptor mechanism {#section22-0269881116654697}
------------------------------------------------------

Although we failed to show the involvement of D~2~ receptor in haloperidol sensitization, given its well characterized antagonism of D~2~ receptors, it seems premature to discount the role of this receptor system in the mediation of antipsychotic sensitization in general. [@bibr38-0269881116654697] used the quinpirole-induced hyperlocomotion test and further investigated the involvement of D~2~ receptor in antipsychotic sensitization. This test is a widely used method assessing drug or non-drug induced changes in D~2~ function ([@bibr163-0269881116654697]; [@bibr173-0269881116654697]). Because quinpirole is a preferential D~2/3~ receptor agonist, and its psychomotor stimulating effect (i.e. increasing locomotor activity) is generally attributed to its selective agonism on D~2~, if a drug-treated rat shows a higher level of motor activity under quinpirole challenge than a vehicle-treated one, it would suggest that the drug causes an upregulation of D~2~ receptor ([@bibr85-0269881116654697]; [@bibr96-0269881116654697]). Indeed, this quinpirole-induced hyperlocomotion has been thought to be mediated through an increase in the efficacy of the post-synaptic D~2~ transduction ([@bibr156-0269881116654697], [@bibr157-0269881116654697]). [@bibr38-0269881116654697] observed that prior risperidone-treated adult rats showed a sensitization effect in the conditioned avoidance response test. Also, they exhibited a significantly higher level of motor activity than the vehicle-pretreated ones when they were all challenged with quinpirole, suggesting that risperidone sensitization is likely mediated by D~2~ receptor supersensitivity ([@bibr136-0269881116654697]). A more recent study from our laboratory showed that aripiprazole-induced sensitization in adult rats is also mediated by drug-induced upregulation of D~2~ receptor ([@bibr40-0269881116654697]). However, antipsychotic sensitization induced during adolescence seems less dependent on D~2~ receptor upregulation, as adult rats that had been treated with risperidone or haloperidol in adolescence failed to show an increased motor activity under the quinpirole challenge, despite the fact that they exhibited a robust sensitization effect ([@bibr39-0269881116654697]; [@bibr110-0269881116654697]). This finding highlights that antipsychotic treatment during the adolescent period may alter D~2~ receptors and others (e.g., 5-HT~2A~, 5-HT~2B~ and 5-HT~1A~) in unique ways not seen in adult animals. Thus, *adolescent* antipsychotic sensitization (or tolerance) may rely on different receptor mechanisms than *adulthood* sensitization. This is because various neurotransmitter systems --- especially the dopamine and serotonin systems in the prefrontal cortex, striatum, and hippocampus --- are still undergoing maturational changes during adolescence ([@bibr17-0269881116654697]; [@bibr162-0269881116654697]). At the present time, available evidence indicates that antipsychotic sensitization induced by olanzapine, risperidone and aripiprazole is likely mediated by D~2~ receptor upregulation, at least in adult rats. The 5-HT~2A~ receptors may also play an important role in this effect as seen in haloperidol sensitization. Clearly, more work is needed to delineate the neuroreceptor mechanisms of antipsychotic sensitization and tolerance.

c-Fos immunocytochemistry study of the neural basis of antipsychotic sensitization {#section23-0269881116654697}
----------------------------------------------------------------------------------

c-Fos, a protein product of immediate-early gene *c-fos* has been used as a molecular biomarker for identifying the neural basis of acute antipsychotic treatment ([@bibr119-0269881116654697]; [@bibr120-0269881116654697]). Acute administration of typical antipsychotic haloperidol and atypical drug clozapine produces a different induction pattern of c-Fos expression in the forebrain, with acute haloperidol increasing c-Fos-positive neurons in the dorsolateral striatum (DLSt), nucleus accumbens shell (NAs) and core (NAc), and lateral septal nucleus (LS) and acute clozapine producing such effects in the NAs, medial prefrontal cortex (mPFC) ([@bibr119-0269881116654697]; [@bibr120-0269881116654697]). Based on these observations, we postulated that by examining how repeated antipsychotic treatment alters c-Fos expression, we may be able to identify the neuroanatomical bases of antipsychotic sensitization or tolerance. In one study ([@bibr184-0269881116654697]), the c-Fos expression in the PCP-induced hyperlocomotion model was examined. Once daily for five days, adult male rats were injected with haloperidol, clozapine or saline, followed by an injection of PCP or saline 30 min later, and motor activity was measured for 90 min after PCP injection. c-Fos immunoreactivity was assessed either after acute (day 1) or repeated (day 5) haloperidol or clozapine tests. Based on the changes of c-Fos expression, a brain region had to meet the following three criteria in order to be considered as part of the neural circuit(s) by which haloperidol and clozapine act to achieve their sensitization or tolerance effect, respectively. First, it should show altered c-Fos expression in response to both acute and repeated treatment of PCP. Second, it should show altered PCP-induced c-Fos expression in response to acute and repeated treatment with haloperidol or clozapine. Third, it should show a change in c-Fos expression from day 1 to day 5. Based on these criteria, three regions including NAs, central amygdala (CeA) and VTA could be classified as part of the haloperidol neural circuit (likely mediating haloperidol sensitization), and three regions including mPFC, ventral part of lateral septal nucleus (LSv) and VTA as part of the clozapine neural circuit (likely mediating clozapine tolerance). It should be pointed out that while c-Fos is an important step in illuminating the differences in neuronal actions between haloperidol and clozapine in this task, these data should be regarded as one piece of evidence toward delineating the neural basis of these drug effects. Thus, other indices such as neurotransmitter release, receptor density changes should be used to validate the current findings in future work.

Central microinjection studies on dopamine D~2~ and 5-HT~2A~ mechanisms {#section24-0269881116654697}
-----------------------------------------------------------------------

Previous studies indicate that down-regulation of 5-HT~2A~ receptors is one of the mechanisms underlying the therapeutic effects of chronic treatment with antipsychotic drugs ([@bibr95-0269881116654697]). Furthermore, our own c-Fos study suggested that the mPFC is part of the neural circuit that mediates the repeated effect of clozapine, e.g. clozapine tolerance. Therefore, it is possible that 5-HT~2A~ receptors in the mPFC might be one of the central receptor mechanisms of clozapine tolerance. We are aware of only one study that tested this hypothesis in the CAR model ([@bibr33-0269881116654697]). In this microinjection study, adult male rats were first trained in the avoidance test and then repeatedly injected with vehicle or clozapine for five days; their avoidance response was tested daily. Fifteen minutes before each daily test, they were also centrally infused with selective 5-HT~2A/2C~ agonist DOI at 0.0, 5.0, or 25.0 µg/0.5 µL/side into the mPFC. It was shown that intra-mPFC infusions of DOI had no effect on the acute avoidance-disruptive effect of clozapine throughout the five test days. One day after the 5^th^ clozapine test, all rats were retrained drug-free to bring their avoidance back to the pre-drug level before the final challenge test to assess the expression of clozapine tolerance. In the challenge test, we found that rats centrally infused with DOI 25.0 µg/0.5 µL/side during the repeated clozapine treatment days did not show higher avoidance than their corresponding vehicle controls, indicating an absence of clozapine tolerance. In other words, activation of 5--HT~2A/2C~ serotonergic receptors in the mPFC by DOI did not affect the acute effect of clozapine, but only abolished clozapine tolerance, suggesting clozapine tolerance is mediated by 5--HT~2A/2C~ receptors in the mPFC. This notion is supported by the subsequent experiment in which we centrally injected DOI 25.0 µg/0.5 µL/side immediately prior to the challenge test. We found that the intra-mPFC infusion of DOI at 25.0 µg/0.5 µL/side prior to the challenge test blocked the expression of clozapine tolerance. Thus, findings from this study confirmed that the mPFC is one critical brain region where clozapine acts to achieve its behavioral effects. It also suggests that the *expression* of clozapine tolerance, but not the tolerance *induction* is dependent on 5-HT~2A/2C~ receptors in the mPFC.

Possible intracellular mechanisms {#section25-0269881116654697}
---------------------------------

Different classes of clinically effective antipsychotics all share a common molecular mechanism involving inhibition of D~2~/β-arrestin-mediated signaling ([@bibr74-0269881116654697]; [@bibr86-0269881116654697]). GSK3β is a key substrate of the dopamine-mediated β-arrestin/Akt signaling pathway and plays a critical role in neuronal development and function, including neurogenesis, axon/dendrite differentiation, neuronal positioning, synaptic transmission and plasticity, and neural apoptosis ([@bibr54-0269881116654697]; [@bibr66-0269881116654697]). Dysregulation of this enzyme activity (e.g. reduced GSK3β protein levels in the prefrontal cortex) has been reported in patients with schizophrenia and mood disorders and in animal models of these mental disorders ([@bibr70-0269881116654697]; [@bibr97-0269881116654697]). Antipsychotic drugs are demonstrated to cause an increase in the phosphorylation of GSK3β and concomitant inhibition of GSK3β activity via antagonizing D~2~ and 5-HT~2A~, and this GSK3β action is thought to mediate the therapeutic effects of antipsychotic treatment ([@bibr15-0269881116654697]; [@bibr37-0269881116654697]; [@bibr65-0269881116654697]; [@bibr80-0269881116654697]). More importantly, such regulation of GSK3β activity has been reported after chronic treatment with antipsychotic drugs, leading us to speculate that inhibition of GSK3β activity by antipsychotic treatment might be one of the mechanisms leading to persistent antipsychotic sensitization from adolescence to adulthood. If this hypothesis were correct, we would expect that (a) antipsychotic treatment would cause a persistent decrease in GSK3β activity (increased phospho-GSK3β); and (b) increasing GSK3β activity would attenuate the antipsychotic sensitization effect induced in both adolescence and adulthood. We recently obtained promising preliminary data consistent with the first expected result. Rats that showed a persistent olanzapine sensitization from adolescence to adulthood had higher levels of p-Akt and p-GSK3β, suggesting that the elevated p-Akt and p-GSK3β may be responsible for this long-lasting effect. Future systemic work needs to further test this hypothesis and determines whether elevated p-Akt and p-GSK3β is responsible for the long-lasting antipsychotic sensitization and tolerance in general.

Summary and future research {#section26-0269881116654697}
===========================

It is well documented now that antipsychotic drugs are exogenous stimuli that impact the brain and cause long-term behavioral changes and associated neuroadaptations. Behaviorally, antipsychotic-induced changes reflect an increase (sensitization) or decrease (tolerance) in drug sensitivity and environmental cues and behavioral response associated with drug treatment have a profound impact on the induction and expression of antipsychotic sensitization and tolerance. Neurochemically, dopamine D~2~ and serotonin 5-HT~2A~ receptors play a role in these two behavioral effects of antipsychotic treatment. Neuroanatomically, the mPFC-related neural circuitry is critically involved in the clozapine tolerance, while other regions (e.g. NAs, VTA, and CeA) may be involved in the mediation of antipsychotic sensitization.

The present paper reviews some of the important evidence in the literature, focusing on the drug-induced changes in antipsychotic response. It is fair to say that although the research community of antipsychotic drugs is relatively large and highly active, this particular field (i.e. research on antipsychotic sensitization and tolerance) is rather small, and much of the work comes from a limited number of laboratories and uses a limited number of animal models (e.g. conditioned avoidance, PCP-induced hyperlocomotion, etc.). Therefore, it is imperative for future research to raise the profile of this area by focusing several areas, as outlined below.

One major area of research is to determine the clinical relevance of antipsychotic sensitization and tolerance. Are they clinically relevant for the explanation of the clinical effects (both therapeutic and side effects) of antipsychotic treatment? What clinical effect could be explained by sensitization and what could be explained by tolerance? What pharmacological features account for the differences between sensitization and tolerance? Why does clozapine primarily cause a tolerance in several behavioral tests of antipsychotic activity, while others induce a sensitization? Could this difference explain the superior treatment effect of clozapine? etc. What clinical phenomena are associated with clozapine tolerance? Clinician scientists could help answer these questions by looking into these two mechanisms as explanatory tools. At this time, it is fair to say that preclinical findings on antipsychotic sensitization and tolerance have not made a good connection with clinical research. Thus basic psychopharmacologists also need to understand clinical phenomena better.

As mentioned, antipsychotic sensitization and tolerance have not been systematically studied in a preclinical disease model of schizophrenia. All the published work so far has been done in otherwise healthy male rats. Therefore, the face validity is low as only humans with severe mental disorders such as schizophrenia receive antipsychotic therapy. Animal work also suggests that antipsychotic treatment has differential effects on "diseased" rodents and normal controls ([@bibr91-0269881116654697]). Thus, one important future focus for basic scientists is to examine antipsychotic sensitization and tolerance in animal models of schizophrenia. Resolving this issue could also help determine the clinical significance of antipsychotic sensitization and tolerance.

To date, limited research is available on the effects of adolescent antipsychotic exposure on basic psychological functions such as attention, novelty-seeking, emotion, and learning and memory ([@bibr92-0269881116654697]; [@bibr172-0269881116654697]). How antipsychotic sensitization and tolerance contribute to these effects has never been explored. Furthermore, whether functional changes in D~2~ and 5-HT~2A~ receptor expressions induced by adolescent antipsychotic treatment are related to drug-induced behavioral effects has not been examined. Future research should fill these knowledge gaps by connecting what we know about the basic behavioral effects of adolescent antipsychotic treatment with the treatment's intrinsic property of altering drug sensitivity. This research will significantly enhance our understanding of the positive and negative impacts of adolescent antipsychotic treatment on drug response, behavioral functions, and brain functions.

Another important research area is to identify the neural mechanisms of antipsychotic sensitization and tolerance. Because antipsychotic drugs have a profound impact on a variety of brain signaling molecules involved in a variety of important yet different brain functions (e.g. synaptic neurotransmission, neuroendocrine regulation, oxidative stress, adult neurogenesis etc.) ([@bibr27-0269881116654697]; [@bibr134-0269881116654697]; [@bibr151-0269881116654697]), and even though we are certain that the sensitization and tolerance induced by these drugs must reflect the consequences of drug-induced neuroplastic changes, we do not fully understand the exact and critical mechanisms underlying the long-term sensitization and tolerance effects. There is not much research that has made an effort to connect drug-induced brain changes at the molecular/system level to the sensitization and tolerance at the behavioral level. This line of inquiry should be one of the focuses of future antipsychotic research. One related area of research is to investigate the neurobiological mechanism underlying the environmental control of the induction and expression of antipsychotic sensitization and tolerance. This work will help us gain better understanding of the neurobiological mechanisms underlying sensitization and tolerance effects.

Also, clinical evidence suggests that women react more favorably to antipsychotic therapy than men ([@bibr158-0269881116654697]), and preclinical evidence also suggests that sex of animals is an important factor in the modulation of antipsychotic response, with females tending to have increased sensitivity to antipsychotic treatment due to lower D~2~ affinity compared to males ([@bibr106-0269881116654697]). Our recent study also indicates that the magnitude of aripiprazole sensitization differs between male and female rats. With NIH's increased emphasis on sex as a biological variable in the design and analysis of NIH-funded research involving animals, determining antipsychotic sensitization and its impact on basic behavioral and brain functions in both male and female animals becomes especially urgent. Unfortunately, all published antipsychotic sensitization studies so far used only male animals. On the dosing regimens, much of this work only used a daily intermittent drug injection schedule for a short period of time (e.g. five days) and most only tested male normal rats, while both clinical and preclinical evidence suggests that females tend to have delayed onset of psychopathology of schizophrenia ([@bibr50-0269881116654697]; [@bibr105-0269881116654697]) and increased sensitivity to antipsychotic treatment due to lower D~2~ affinity compared to males ([@bibr106-0269881116654697]). It is thus important to examine sex differences in antipsychotic sensitization and tolerance and use a variety of different dosing regiments, such as continuous treatment via osmatic minipumps or drinking water or prolonged treatment for months.
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